阿扎胞苷单药或联合HAG 方案在骨髓增生异常综合征中的临床观察.

To explore the clinical efficacy and safety of azacitidine(AZA) or combined with HAG regimen in the treatment of myelodysplastic syndrome (MDS). The clinical data of 49 patients with MDS in our hospital were retrospectively analyzed. According to different treatment methods, they were divided into supportive treatment group and AZA containing group (AZA or combined with HAG regimen). The clinical efficacy and adverse reactions of the patients were statistically analyzed. In the supportive treatment group, the overall response rate (ORR) was 30.00%, including 0 case complete remission (CR), 1 case of bone marrow complete remission (mCR), 2 cases of partial remission (PR), 3 cases of hematological improvement (HI). The ORR of the AZA containing group was 65.52%, including 8 cases CR, 2 case mCR, 4 cases PR and 5 cases HI. The ORR of monotherapy group was 46.67%, including 2 cases CR, 1 case mCR, 2 cases PR, 2 cases HI. The ORR of combination group was 85.71%, including 6 cases CR, 1 case mCR, 2 cases PR, 3 cases HI. Compared with the supportive treatment group, the complete remission rate and ORR in the group containing AZA were significantly higher than those in the treatment group, and the difference was statistically significant(P<0.05). After receiving AZA containing regimen, the most common adverse reactions were grade III-IV myelosuppression (18/29) and secondary infection (10/29), and the incidence gradually decreased with the increase of treatment courses. Compared with the supportive treatment group, the median Overall survival time and median Progression-free survival time of patients with AZA were significantly longer (P＜0.05). The results of this small sample retrospective case study show that compared with supportive treatment, AZA or combined with HAG regimen has a higher response rate in the treatment of MDS patients, can prolong the overall survival time of patients, and is well tolerated. And combination therapy may have a better effect. [ABSTRACT FROM AUTHOR]